Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-11-23
1999-03-16
Feisee, Lila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 245, 536 231, 4241521, C07H 2104, A61K 4800
Patent
active
058830820
ABSTRACT:
Compositions and methods are provided for the prevention and treatment of allograft rejection. Compositions are provided which comprise an antisense oligonucleotide targeted to a nucleic acid sequence encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, or endothelial leukocyte adhesion molecule-1 in combination with an immunosuppressive agent. Methods of preventing or treating allograft rejection by treating an allograft recipient with such a composition are provided. Methods for preventing allograft rejection comprising perfusion of the graft are also provided.
REFERENCES:
patent: 5284931 (1994-02-01), Springer et al.
patent: 5514788 (1996-05-01), Bennett et al.
patent: 5580969 (1996-12-01), Hoke et al.
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5596090 (1997-01-01), Hoke et al.
Chen et al., "Mechanism of Action of the Novel Anticancer Agent 6-Fluoro-2(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic Acid Sodium Salt (NSC 368390): Inhibition of de Novo Pyrimidine Nucleotide Biosynthesis," Cancer Res. 1986, 46, 5014-5019.
Chou, T-C. et al., "Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs of Enzyme Inhibitors," Adv. Enz. Regul. 1984, 22, 27-55.
Haug et al., "A Phase I Trial of Immunosuppression with Anti-ICAM-1 (CD54) mAb in Renal Allograft Recipients," Transplantation 1993, 55, 766-773.
Kitajima et al., "Ablation of Transplanted HTLV-I Tax-Transformed Tumors in Mice by Antisense Inhibition of NK-.sub.k B," Science 1992, 258, 1792-1795.
Liu et al., "Calcineurin is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes," Cell 1991, 66, 807-815.
Monaco et al., "Studies on Heterologous Anti-Lymphocyte Serum in Mice," J. Immunol. 1966, 96, 229-238.
Morice et al., "Rapamycin-Induced Inhibition of p34.sup.cdc2 Kinase Activation is Associated with G.sub.1 /S-Phase Growth Arrest in T Lymphocytes," J. Biol. Chem. 1993, 268, 3734-3738.
Nickoloff et al., "Accessory Cell Function of Keratinocytes for Superantigens," J. Immunol. 1993, 150, 2148-2159.
Simons et al., "Antisense c-myb Oligonucleotides Inhibit Intimal Arterial Smooth Muscle Cell Accumulation in vivo," Nature1992, 359, 67-70.
Adams et al., Intercellular Adhesion Molecule 1 on Liver Allografts During Rejection, Lancet 1989, 1122-1125.
Bevilacqua et al., Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neutorophils Related to Complement Regulatory Proteins and Lectins, Science 1989, 243, 1160-1165.
Bevilacqua et al., Identification of an Inducible Endothelial-leukocyte Adhesion Molecule, Proc. Natl. Acad. Sci. USA 1987, 84, 9238-9242.
Cosimi et al., In vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) in Nonhuman Primates with Renal Allografts, J. Immunol. 1990, 144, 4604-4612.
Faull et al., Tubular Expression of Interecellular Adhesion Molecule-1 During Renal Allograft Rejection, Transplantation 1989, 48, 226-230.
Frohman et al., The induction of intercellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-.gamma., tumor necrosis factor .alpha., lymphotoxim, and interleukin-1: relevance to intracerebral antigen presentation, J. Neuroimmunol. 1989, 23, 117-124.
Harlan, J.M., Leukocyte-Endothelial Interactions, Blood 1985, 65, 513-525.
Isobe et al., Specific Acceptance of Cardiac Allograft After Treatment with Antibodies to ICAM-1 and LFA-1, Science 1992, 255, 1125-1127.
Isobe et al., Early Detection of Rejection and Assessment of Cyclosporine Therapy by .sup.111 In Antimyosin Imaging in Mouse Heart Allografts, (1991) Circulation 84:1246-1255.
Nielsen et al., Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide, Science 1991, 254, 1497.
Osborn et al., Direct Expression Cloning of Vasular Cell Adhesion Molecule 1, a Cytokine-Induced Endothelial Protein that Binds to Lymphocytes, Cell 1989 59:1203-11.
Rice et al., An Inducible Endothelial Cell Surface Glycoprotein Mediates Melanoma Adhesion, Science 1989, 246, 1303-1306.
Rice et al., Inducible Cell Adhesion Molecule 110 (INCAM-110) is an Endothelial Receptor for Lymphocytes, J. Exp. Med. 1990, 171, 1369-1374.
Staunton et al., Primary Structure of ICAM-1 Demonstrates Interaction between Members of the Immunoglobulin and Integrin Supergene Families, Cell 1988, 52, 925-933.
Wellicome et al., A Monoclonal Antibody that Detects a Novel Antigen on Endothelial Cells that is Induced by Tumor Necrosis Factor, IL-1, or Lipopolysaccharide, J. Immunol. 1990, 144, 2558-2565.
Zuker, M., On Findings All Suboptimal Foldings of an RNA Molecule, Science 1989, 244, 48-52.
Chiang, M Y et al. 1991. JBC. 266(27): 18162-18171.
Kalian, B.D. et al. 1993. Transplantation 55:894-900.
Monaco, A.P. et al 1966. J. Immunol. 96(2):229-238.
Bennett C. Frank
Stepkowski Stanislaw M.
Bansal Geetha P.
Board of Regents , The University of Texas System
Feisee Lila
ISIS Pharmaceuticals Inc.
LandOfFree
Compositions and methods for preventing and treating allograft r does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for preventing and treating allograft r, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for preventing and treating allograft r will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-817844